This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes. - Monotherapy - Combined therapy
Long-term treatment of patients aged 12 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) who have an amenable mutation.
Mircera is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia associated with chronic kidney disease (CKD in adult patients on dialysis and patients not on dialysis
1) The treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) 2) The treatment of adults with newly diagnosed AML with myelodysplasia-related changes (AML-MRC)
Co-administration with heparin in the patients who are: - target patients in the treatment of acute coronary syndrome (ACS) - patients with percutaneous transluminal coronary angioplasty (PTCA) or atherectomy